J&J denied extension of patent on TB drug, to benefit patients | India News – Times of India
New Delhi: In a move that will benefit tuberculosis patients, Indian Patent Office (IPO) has denied the US giant Johnson & Johnson’s request to extend its patent on the life-saving TB drug Bedaquiline. This ruling potentially facilitates the entry of affordable versions of the long-acting injectable Bedaquiline over the next few years, improving access for…